BVS News and Press, Bioventus Inc. From 07/26/22

DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 be...

Gainers: ironSource ( IS ) +48% . Liberty TripAdvisor Holdings ( LTRPB ) +47% . XORTX Therapeutics ( XRTX ) +38% . Boxed ( BOXD ) +29% . TDH Holdings ( PETZ ) +25% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuti...

DURHAM, N.C., July 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal. “We are excited to...

DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an amendment to the Option and Equity Purchase Agreement f...

Bioventus' diversified portfolio insulates the company from peers and enables it to innovate around its core offering. The company holds market-leading positions in several complex pain segments, offering non-invasive treatment solutions. There are high earnings and FCF growth pot...

Bioventus Inc. (BVS) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Dave Crawford - Vice President of Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Office Conference Call Participants Alex Nowak...

Image source: The Motley Fool. Bioventus Inc. (NASDAQ: BVS) Q1 2022 Earnings Call May 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Bioventus Inc. (BVS) Q1 2022 Earnings Call Transcript

The following slide deck was published by Bioventus Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Bioventus Inc. 2022 Q1 - Results - Earnings Call Presentation

Bioventus press release (NASDAQ:BVS): Q1 GAAP EPS of -$0.19. Revenue of $117.29M (+43.4% Y/Y). Reaffirms 2022 Guidance: Net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31%. Adjusted EBITDA of $94 million to $107 million, compared to $...

DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 2, 2022. Q1 Financial Summary & Recent Highlights: ...